Surgical and Locoregional Therapy of HCC: TACE

Liver Cancer

Volumn 4, Issue 3, 2015, Pages 165-175

  Tsurusaki, Masakatsu ^a   Murakami, Takamichi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Chemoembolization; Drug eluting bead; Gelatin sponge; Hepatocellular carcinoma; Iodized oil

Indexed keywords

IODINATED POPPYSEED OIL; NANOBEAD; SORAFENIB;

CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; DRUG ELUTING BEAD; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84992210834     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367739     Document Type: Review

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401.
3. Nakamura H, Hashimoto T, Oi H, Sawada S: Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-786.
4. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, Maeda M, Yoshioka T: Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an chemotherapeutic drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1990;13:140-145.
5. Nakao N, Kamino K, Miura K, Takayasu Y, Ohnishi M, Miura T: Transcatheter arterial embolization in hepatocellular carcinoma: a long-term follow-up. Radiat Med 1992;10:13-18.
6. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83.
7. Nishimine K, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, Guo Q, Ohishi H, Nagano N, Yoshioka T, et al: Segmental transarterial chemoembolization with Lipiodol mixed with chemotherapeutic drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 1994;33(Suppl):S60-S68.
8. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
9. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
10. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
11. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
12. Ekelund L, Lin G, Jeppsson B: Blood supply of ex-perimental liver tumors after intraarterial embolization with Gelfoam powder and absolute ethanol. Cardiovasc lntervent Radiol 7: 234-239, 1984.
13. Takaki S, Sakaguchi H, Anai H, et al. : Long-term outcome of transcatheter subsegmental and segmental arterial chemoembolization using lipiodol for hepatocellular carcinoma. Cardiovasc lntervent Radiol 35: 544-554, 2012.
14. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(Suppl 1):S179-S188.
15. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
16. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235.
17. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
19. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
20. Kudo M, Matsui O, Izumi N, et al: JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468.
21. Miyayama S, Matsui O, Yamashiro M. et al. :Ultraselective transcatheter arterial chemoembolization with a2-f tip microcatheter for small hepatocellular carcinomas: Relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc lnterv Radiol l8: 365-376. 2007.
22. Kora S, Urakawa H, Mitsufuji T, el al. :Warming effect of miliplatin-lipodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc lnlervent Radiol 36: 1023-1029. 2013.
23. Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H: Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 2013;43:942-949.
24. Miyayama S, Yamashiro M, Hashimoto M, Hashimoto N, Ikuno M, Okumura K, Yoshida M, Matsui O: Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ?6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. Cardiovasc Intervent Radiol 2014;37:388-395.
25. Minami Y, Yagyu Y, Murakami T, Kudo M: Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer 2014;3:53-61.
26. Miyayama S, Yamashiro M, Hashimoto M, Hashimoto N, Ikuno M, Okumura K, Yoshida M, Matsui O: Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol 2013;24:501-508.
27. Yamakado K, Miyayama S, Hirota S. et al. :Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radio1 30: 560-566, 2012.
28. Takayasu K, Arij S, Kudo M, et al. :Superselective transarterial chemoembolization for hepatocellular carcinoma. validation of treatment algorithm proposed by Japanese guidelines. J Hepato1 56;886-892, 2012.
29. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radio1 33: 41-52, 2010.
30. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS: Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010;101:476-480.
31. Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc lnterv Radio1 22: 1545-1552, 2011.
32. Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, Necozione S, Desideri G, Rea S: Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin?eluting beads compared with lipiodol. Oncol Rep 2012;27:1377-1383.
33. Song MJ, Chun HJ, Song S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK: Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244-1250.
34. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP: Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255-264.
35. Liapi E, Lee KH, Georgiades CC, Hong K, Geschwind JF: Drug-eluting particles for interventional pharmacology. Tech Vasc Interv Radiol 2007;10:261-269.
36. Malagari K: Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Chemotherapeutic Ther 2008;8:1643-1650.
37. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-1335.
38. Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc lntervent Radio1 35: 1119-1128, 2012.
39. Kim HY, Park JW: Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer 2014;3:9-17.
40. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-2127.
41. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol. 2012;30 (suppl 4; abstr LBA154).
42. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
43. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-829.
44. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012;48:1452-1465.
45. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW: Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006;17:1335-1343.
46. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C: Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drugeluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011;197:W562-570.
47. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-124.